JAK2 and acute myeloid leukemia: A significant clinical heterogeneity, ranging from common chronic course to less frequent evolution to AML [13], [16]–[18], exists among classical MPD patients with the JAK2 V617F mutation, and is even more diverse in patients with MDS/MPD overlap.